Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765211 | 0.89 | PDE5A (0.49) | KIF11PDE5AKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL764990 | 0.89 | PDE5A (0.55) | KIF11PDE5AKDM4EABCG2LMNA | |
| SCHEMBL1120736 | 0.82 | KIF11 (0.77) | KIF11ABCG2LMNATP53 | |
| SCHEMBL8403051 | 0.79 | KIF11 (0.49) | KIF11PDE5A | |
| SCHEMBL11912538 | 0.78 | KIF11 (0.56) | KIF11PDE5A | |
| SCHEMBL3343352 | 0.78 | KIF11 (0.43) | KIF11PDE5AKDM4EABCG2 | |
| SCHEMBL3348319 | 0.78 | PDE5A (0.54) | KIF11PDE5AKDM4ESMN1; SMN2ABCG2 | |
| SCHEMBL25423992 | 0.77 | HTR2A (0.51) | KIF11PDE5A | |
| SCHEMBL25424698 | 0.77 | HTR2A (0.51) | KIF11PDE5A | |
| SCHEMBL8404344 | 0.77 | KIF11 (0.81) | KIF11ABCG2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-8076352-B2 | Administration of carboline derivatives useful in the treatment of cancer and other diseases | PTC THERAPEUTICS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110160190-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-7767689-B2 | Carboline derivatives useful in the treatment of cancer | PTC THERAPEUTICS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100125065-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-05-20 | — | — | US | disclosed |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | VEGFA, FLT4, FLT1 | KIF11 2495/4885PDE5A 1449/4885KDM4E 730/4885 |
| US-20110160190-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | KIF11 3253/4885PDE5A 601/4885KDM4E 407/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | KIF11 2495/4885PDE5A 1449/4885KDM4E 730/4885 |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | KIF11 2890/4885PDE5A 827/4885KDM4E 418/4885 |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | VEGFA, FLT4, KDR | KIF11 3727/4885PDE5A 200/4885KDM4E 968/4885 |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | KIF11 3253/4885PDE5A 601/4885KDM4E 407/4885 |
| US-20100125065-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, KDR | KIF11 3727/4885PDE5A 200/4885KDM4E 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.